Cover Image

Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy

Background: Psoriasis is an immune-mediated inflammatory disease characterized by activation of IL-23-driven IL-17-producing T cell and other IL-23 receptor-positive IL-17-producing cell responses. Selective blockade of IL-23p19 with guselkumab was superior to blockade of TNF-α with adalimumab (ADA)...

Full description

Saved in:

Bibliographic Details
Main Authors:	Andrew Blauvelt (Author), Richard G. Langley (Author), Patrick J. Branigan (Author), Xuejun Liu (Author), Yanqing Chen (Author), Samuel DePrimo (Author), Keying Ma (Author), Brittney Scott (Author), Kim Campbell (Author), Ernesto J. Muñoz-Elías (Author), Kim A. Papp (Author)
Format:	Book
Published:	Elsevier, 2024-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy
by: Andrew Blauvelt, et al.
Published: (2024)

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Andrew Blauvelt, et al.
Published: (2023)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023)

Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2
by: Byung Soo Kim, et al.
Published: (2023)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023)

Guselkumab in Patients with Scalp Psoriasis: A post hoc Analysis of the VOYAGE 2 Phase III Randomized Clinical Trial
by: Enikö Sonkoly, et al.
Published: (2024)

Guselkumab - In Psoriasis and Beyond
by: Aditya Kumar Bubna, et al.
Published: (2024)

Outpatient services and primary care: scoping review, substudies and international comparisons
by: Eleanor Winpenny, et al.
Published: (2016)

Effect of guselkumab on serum biomarkers in Japanese palmoplantar pustulosis patients in a randomized phase 3 study
by: Akimichi Morita, et al.
Published: (2023)

The Dread Voyage: Poems
by: Campbell, Wilfred, 1858?-1918

Guselkumab for the treatment of psoriasis - evidence to date
by: Miguel Nogueira, et al.
Published: (2019)

Importance of Active Participation in Obesity Management Through Mobile Health Care Programs: Substudy of a Randomized Controlled Trial
by: Oh, Bumjo, et al.
Published: (2018)

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
by: Li Y, et al.
Published: (2022)

Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial
by: Luis Puig, et al.
Published: (2024)

Usage of a Generic Web-Based Self-Management Intervention for Breast Cancer Survivors: Substudy Analysis of the BREATH Trial
by: van den Berg, Sanne W, et al.
Published: (2013)

Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis
by: April W. Armstrong, et al.
Published: (2024)

Reproducibility of Bioelectrical Impedance Analysis in Pregnancy and the Association of Body Composition with the Risk of Gestational Diabetes: A Substudy of MUMS Cohort
by: Michelle Bai, et al.
Published: (2020)

Modified dose of guselkumab for treatment of pyoderma gangrenosum
by: Ashley M. Reese, BS, et al.
Published: (2022)

Successful treatment of generalized pustular psoriasis with guselkumab
by: Martina Part
Published: (2024)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
by: Yijia Jiang, et al.
Published: (2023)

Guselkumab as a treatment option for recalcitrant pyoderma gangrenosum
by: Cassandra Baier, MS, PA-C, et al.
Published: (2021)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
by: Fabrizio Martora, MD, et al.
Published: (2023)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
by: Erin Bartholomew, et al.
Published: (2023)

Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab
by: Reem Kashlan, MPH, et al.
Published: (2021)

The acceptability of implementing telemedicine for early medical abortion in South Africa: A substudy to a randomized controlled trial
by: Oluwaseyi Dolapo Somefun, et al.
Published: (2023)

Adalimumab
by: Nilgun Atakan
Published: (2022)

Recalcitrant erythrodermic ichthyosis with atopic dermatitis successfully treated with Dupilumab in combination with Guselkumab
by: M. Steinhoff, et al.
Published: (2022)

Transcription Factor IRF7 is Involved in Psoriasis Development and Response to Guselkumab Treatment
by: Yuan X, et al.
Published: (2024)

Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT
by: Colomba Falcone, et al.
Published: (2012)

Treatment of refractory dissecting cellulitis of the scalp with guselkumab: Case report
by: Sonal Muzumdar, et al.
Published: (2020)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021)

Pityriasis Rubra Pilaris refractory to ustekinumab successfully treated with guselkumab
by: João Teixeira, et al.
Published: (2024)

Plantar pustules in a psoriasis patient during the guselkumab therapy
by: Shinsuke Nakazawa, et al.
Published: (2021)

Exercise training response according to baseline ferrokinetics in heart failure with preserved ejection fraction: A substudy of the TRAINING‐HF trial
by: Patricia Palau, et al.
Published: (2024)

Seven cancer patients receiving Guselkumab for treatment of moderate-to-severe psoriasis
by: Luca Mastorino, et al.
Published: (2022)

Erythrodermic psoriasis treatment with Guselkumab: report of two cases and literature review
by: Esperanza Welsh, et al.
Published: (2024)

Multirefractory bullous pemphigoid, psoriasis and psoriatic arthritis successfully treated with guselkumab
by: Francisco José Rodríguez-Cuadrado, et al.
Published: (2024)

Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
by: Yang EJ, et al.
Published: (2019)

Treatment of granulomatous rosacea with adalimumab
by: Ryan C. Saal, BS, et al.
Published: (2023)

Tracking and prevalence of cardiovascular disease risk factors across socio-economic classes: A longitudinal substudy of the European Youth Heart Study
by: Bai Charlotte N, et al.
Published: (2006)